National Health Act 1953 - Amendment determination under section 84AH - exempt items (No. PB 69 of 2008)

Overview

The National Health Act 1953, amended in 2008 through the instrument F2008L02060, addresses the need for more tailored pharmaceutical benefits under the Pharmaceutical Benefits Scheme (PBS). The Act, enacted by the Australian Parliament, aims to ensure that all Australians have reliable, timely, and affordable access to a wide range of medicines. The 2008 amendments, particularly through the insertion of section 84AH, allow the Minister for Health to declare certain pharmaceutical items as "exempt items" under specific conditions. This includes situations where there is only one listed brand of a pharmaceutical item, no bioequivalent or biosimilar brands are available, and the drug is common to at least one brand of another pharmaceutical item. The exemption aims to encourage the availability of particular drug formulations, such as oral solutions, that are suitable for specific patient subgroups, like children or geriatric patients, where other formulations are unsuitable. This legislative change seeks to balance the need for price control with the necessity of providing suitable therapies for particular patient populations.

Scope and Application

The National Health Act 1953, as amended, governs the Pharmaceutical Benefits Scheme (PBS) through which the Australian Commonwealth ensures accessible, reliable, and affordable medicines for all Australians. Specifically, Part VII of the Act outlines the legislative basis for the PBS and mandates the Commonwealth to provide benefits for pharmaceutical items in accordance with this part. The Minister for Health is authorised to declare drugs and medicinal preparations as listed drugs under the Act, thereby bringing them within the scope of the PBS. These declarations are made through legislative instruments that specify the form and manner of administration of the listed drugs. The amendments introduced by the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2007, including the insertion of section 84AH, allow the Minister to determine certain pharmaceutical items as "exempt items" from statutory price reductions and price disclosure requirements if specific conditions are met. This includes scenarios where there is only one listed brand of a pharmaceutical item, no bioequivalent or biosimilar brands exist, and the drug in the item is common to at least one other brand of pharmaceutical item. The intent behind these exemptions is to promote availability for specific formulations of drugs, such as oral solutions for children or geriatric patients, when other formulations are unsuitable. The amendments to the determination under section 84AH, as outlined in the Schedule of the legislative instrument, adjust the list of exempt items by adding and deleting certain pharmaceutical items, effective from 1 July 2008.

Key Provisions

The National Health Act 1953 (the Act) governs the Pharmaceutical Benefits Scheme (PBS), enabling the Commonwealth to provide affordable access to medicines for Australians (subsection 85(1)). Under this Act, the Minister is empowered to declare drugs and medicinal preparations as listed drugs (subsection 85(2)). These declarations determine the form and administration of pharmaceutical benefits and brands of pharmaceutical items (subsections 85(3), 85(5), and 85(6)). The Act has been amended to introduce section 84AH, allowing the Minister to designate certain pharmaceutical items as "exempt items" if specific criteria are met, such as the presence of a single listed brand and suitability for a particular patient population (subsection 84AH). Exempt items are exempt from statutory price reductions and price disclosure requirements. The Act imposes obligations on pharmaceutical companies and other entities involved in the PBS. Pharmaceutical companies must ensure their drugs are listed appropriately and comply with any declarations made by the Minister. They must also adhere to the provisions concerning brands of pharmaceutical items, including statutory price reductions, price disclosure, and guarantees of supply. The Minister, in consultation with the Pharmaceutical Benefits Advisory Committee (PBAC), has the authority to make determinations regarding exempt items. These determinations must be based on the suitability of the drug for a specific patient population and the form and manner of administration. Failure to comply with the provisions of the Act can result in various consequences. For example, pharmaceutical companies that do not list their drugs correctly or fail to comply with price disclosure requirements may face penalties. The exact penalties are not specified in the Act but could include fines or other administrative actions. Additionally, any misrepresentation or fraudulent behaviour in the listing or administration of pharmaceutical benefits could lead to criminal charges, resulting in significant fines and potential imprisonment. The precise penalties depend on the nature and severity of the breach.